Was it worth introducing health economic evaluation of innovative drugs in the french regulatory setting : the case of new drugs against Hepatitis C Virus - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Value in Health Année : 2018

Was it worth introducing health economic evaluation of innovative drugs in the french regulatory setting : the case of new drugs against Hepatitis C Virus

Résumé

The paper draws lessons from the recent uptake of health economic evaluation of innovative drugs in the French regulatory framework.Taking the example of new direct-acting antivirals against Hepatitis C virus the paper asks whether and how the Cost-Effectiveness (CE) Opinions issued by the French National Health Authority improve the information available to support the pricing decisions.The results show that CE Opinions bring to the fore 3 issues prone to impact the Incremental Cost Utility Ratio and that were not available to the decision-maker through Clinical Opinions or published CUA: the stage of treatment initiation, the modeling of the disease progression and the uncertainty around the efficacy rates.
Fichier principal
Vignette du fichier
S1098301518361436.pdf (158.56 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-01907811 , version 1 (22-10-2021)

Licence

Identifiants

Citer

Valérie Clément, Véronique Raimond. Was it worth introducing health economic evaluation of innovative drugs in the french regulatory setting : the case of new drugs against Hepatitis C Virus. Value in Health, In press, ⟨10.1016/j.jval.2018.08.009⟩. ⟨hal-01907811⟩
81 Consultations
52 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More